About Sollers

Sollers is a graduate school located in New Jersey, specializing in clinical research, drug safety and pharmacovigilance training.

Our graduate certificate and masters programs cover a wide range of subjects tailored to this fast growing industry, and our graduates go on to highly successful careers in the pharmaceuticals industry and healthcare industries.

  • HOURS
  • Monday - Thursday | 10 AM - 7 PM
  • Friday | 12 PM - Midnight
  • Saturday | 12 PM - Midnight
  • Sunday | Closed
  • OPEN 24/7 - sollers.edu
    • PHONE
    • (848) 299-5900
    • Location
    • 100 Menlo Park, Suite 550
      Edison New Jersey 08837 -2488

Location

Call Us Now: 848 299-5900

Sollers Blog

Outcome Health, Harward Health Publications forge alliance to improve digital platforms in clinics

Posted by Doctor Dan on Oct 19, 2017 3:06:21 PM

Fresh off a $500 million first financing round in late May this year, Outcome Health has already set out to improve its health intelligence offerings with the help of a new collaborator: Harvard Health Publications, Angus LLu, Associate Editor, writes on Fiercebiotech.com.

Read More

Topics: Clinical Research

Healthcare Data Science for Quality Improvement and Patient Safety

Posted by Doctor Dan on Oct 17, 2017 1:47:00 PM

In order to reap the benefits of data, it calls for evolving an organization-wide data science strategy. What with many other segments such as banking has adopted Data Science, health care is an exception. With the absence of a data science strategy, healthcare firms find it difficult to handle the increasing volume of data. Also individual clinicians find it cumbersome to improve the safety, quality and efficiency of the care they provide. An effective data science strategy for health care organizations is therefore, the need of the hour, says, a catalyst.nejm.org report. Data Science has five key components.

Read More

Topics: Data Science

Bio-containment, Comprehension of Bio-safety Levels

Posted by Doctor Erick on Oct 12, 2017 2:41:40 PM

Bio-containment has potent compounds, focused primarily on chemically derived drug substances and drug components, while analogous to chemical potent compounds. Biologically derived ingredients, intermediates, and products are produced by human manipulation of naturally occurring life forms and their by-product write Herman F. Bozenhardt and Erich H. Bozenhardt in pharmaceuticalonline.com.

Read More

Topics: Drug Safety

LifeSphere intake and triage to improve efficiency, eliminate manual data

Posted by Phil on Oct 11, 2017 2:51:14 PM

Multi-tenant cloud solution acts as a front end to any safety database and integrates with mobile-based applications to automate and standardize the case intake process for reports received from the field, reducing costs for greater ROI, says an ArisGlobal statement.

Read More

Topics: Clinical Research

Drug Storage Compliances

Posted by Doctor Erick on Oct 10, 2017 2:58:06 PM

Drug storage compliance programs do not create or confer any rights for or on any person and does not operate to bind USFDA or the public. An alternative approach may be used as long as the approach satisfies the requirements of the applicable statutes and regulations. The drug storage compliance programs provide ways, by which assurance of safety and effective drugs could be made possible to people by protecting them from unsafe, ineffective and poor quality drugs.

Read More

Topics: Drug Safety

eTMFs Are Transforming the Pharmaceutical Industry

Posted by Doctor Dan on Oct 9, 2017 2:50:27 PM

According to a last year’s research on checking the pulse of the pharmaceutical industry’s use of trial master file (TMF) and collating feedback from 217 TMF managers from across the globe shows humongous change is under way as the industry shifts from passive to active TMF management and adopts advanced electronic TMF (eTMF) applications to improve inspection readiness and shorten clinical trial times, Rik van Mol, Vice President of R&D Strategy, Europe, at Veeva Systems, responsible for the Veeva Vault R&D suite of applications writes on pharmexec.com.

Read More

Topics: Clinical Research

Ethics of Human Research Subjects, Synopsis

Posted by Doctor Dan on Oct 4, 2017 12:57:08 PM

As early as January 18, this year, the US Department of Health and Human Services (HHS), via the Office of Human Research and Protection (OHRP), released the final regulations (the Final Rule), bringing about notable changes to the Federal Policy for the Protection of Human Subjects (The Common Rule), according to a Hallrender.com report.

Read More

Topics: Drug Safety

Natural Language Processing Market to touch $22.3 billion by 2025

Posted by Doctor Erick on Sep 29, 2017 2:32:00 PM

Natural language processing (NLP) is a technology spawned from the need for machines to understand and communicate with humans in human language, not formal computer languages, says a company statement.

Read More

Topics: Data Science

Global Pharmaceutical Industry to Grow at a CAGR of 4-7% during the next five years

Posted by Doctor Dan on Sep 28, 2017 1:36:20 PM

Total spending on medicines is projected to touch $1.5 trillion by 2021, up 33% from 2016 levels even as annual growth moderates from the record pace set in 2014 and 2015, writes Patricia Van Arnum on connect.dcat.org. The recent analysis by QuintilesIMS forecasts that the global pharmaceutical industry will grow at a compound annual growth rate of 4-7% during the next five years, down from the nearly 9% growth level seen in 2014 and 2015.

Read More

Topics: Drug Safety

QSP Enhances Value to Drug Development

Posted by Phil on Sep 25, 2017 12:56:27 PM

The pharmaceutical industry is huge and has a direct impact on millions of patients across the world and the industry deals with a large amount of crucial data that needs to be organized, processed, and worked on effectively for efficient patient care and valuable drug development.

Read More

Topics: Drug Safety